🔗 Share this article

As America continues making sweeping revisions to its immunization guidelines, one figure has surfaced unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccines during the global health crisis and has focused upon potential deaths after COVID-19 vaccination in her brief position at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Program

Agency leaders were set to announce major changes to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US at odds with many the world with insufficient data for public health gain. The planned update has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is listed to address the audience at the event. She was just designated acting director of the FDA’s drug evaluation center, the fifth person to run the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a greater focus upon dismantling long-standing immunizations at the FDA.

Høeg has repeatedly called for ending some childhood immunization guidelines in the US to become more similar to the Danish model, a nation with nationalized medicine and a population approximately the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on immunizations – typically the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Expertise

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or administrative roles, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and CBER since spring.

“She appears not to have any of the qualifications” for running the CDER, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in managing a major agency. She has no expertise in pharmaceutical oversight.”

Past commissioners of CBER would “grasp laws and regulations and the research of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

CDER has an immense range of responsibilities at the FDA, she pointed out.

“Everybody just focuses on the innovative therapies, but the generic program authorizes numerous off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and more, and all of those have to be managed,” Dr. Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a substantial leadership aspect to the job, which manages over 5,000 personnel. “It is a massive administrative position, if you do it right,” she concluded.

Response and Disputed Policies

In response to questions about Høeg’s fitness for the role and whether this selection indicates more teamwork among agency officials on immunizations, a representative responded that the “concerns stem from incorrect presumptions”.

“This background aligns with the duties of her role,” the spokesperson stated, noting the months Dr. Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg takes over the commissioner’s new priority voucher program, a controversial expedited therapy clearance system that reportedly worried her predecessors. “How are these medications being selected for this voucher program? Who is making the choices?” Dr. Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

In general, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, aside from vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if problematic, track record, Howard have noted. She released a research paper using unverified crowd-sourced reports to determine the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to imply Covid vaccines are more dangerous than they are.

Among her “wish list” for the incoming government encompassed changing regulations for novel immunizations and ending “unnecessary” immunizations, she stated post-election on a online show. At the agency, Høeg has according to sources suggested barring adolescent males from getting Covid vaccines.

“She’s an complete ideologue who starts off with her beliefs and works backwards to fit the evidence in a extremely misleading, dishonest fashion,” Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow skeptics, {like|